# Cereno Scientific > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/cerenoscientific). ## Overview Cereno Scientific is a Swedish clinical-stage biotech company developing epigenetic therapies for rare cardiovascular and pulmonary diseases. Its pipeline centers on HDAC-modulating programs, including CS1, CS014 and CS585, which are being advanced through preclinical and clinical development. ## Products & services • CS1: HDAC inhibitor program for pulmonary arterial hypertension • CS014: HDAC inhibitor program in clinical development • CS585: Selective prostacyclin (IP) receptor agonist • Preclinical and translational research programs • Clinical development and regulatory advancement - **CS1 clinical program** (40%) — Development of CS1 for pulmonary arterial hypertension and related cardiopulmonary indications. - **CS014 clinical program** (30%) — Development of CS014 through early clinical testing and Phase II preparation. - **CS585 preclinical program** (20%) — Preclinical development of CS585, a selective prostacyclin receptor agonist. - **Research, regulatory and partnering activities** (10%) — Translational research, regulatory work, and external partnering support across the pipeline. - CS1: HDAC inhibitor program for pulmonary arterial hypertension - CS014: HDAC inhibitor program in clinical development - CS585: Selective prostacyclin (IP) receptor agonist - Preclinical and translational research programs - Clinical development and regulatory advancement ## Customers Cereno Scientific does not sell commercial medicines today; its direct counterparties are regulators, clinical trial participants, research partners, and potential licensing partners. The eventual end customers for its therapies are patients with rare cardiovascular and pulmonary diseases, especially pulmonary arterial hypertension and related conditions. - **Patients with rare cardiopulmonary disease** (primary) — Ultimately buy the therapeutic benefit through prescribed medicines for PAH and related indications. - **Pharmaceutical licensing partners** (secondary) — May partner on later-stage assets that show differentiated clinical and regulatory progress. - **Clinical research ecosystem** (secondary) — CROs, investigators, and academic collaborators support trial execution and data generation. - **Regulators** (secondary) — FDA and other agencies review trial design, safety, and development pathways. - Patients with pulmonary arterial hypertension and related rare diseases - Clinical investigators and trial sites running the studies - Regulators such as the FDA reviewing development plans - Academic and CRO partners supporting research execution - Potential pharma partners evaluating licensing or collaboration ## Geography Cereno Scientific is headquartered in Sweden and operates as a Nordic biotech with a global clinical and partnering footprint. Its development work is international, with collaborations in the United States and participation in conferences and partnering events across Europe, North America and Asia. - Sweden is the corporate base and main operating center - United States is important for FDA interaction and clinical development - Europe is a core region for scientific conferences and partnering - Global partnering events support investor and licensing outreach - Clinical work is outsourced and collaborative across multiple countries ## Strategy Cereno Scientific’s strategy is to advance its HDAC-based pipeline through clinical milestones that reduce development uncertainty and increase partnering value. The company also uses regulatory designations, external collaborations, and a lean operating model to progress multiple programs while preserving flexibility. - **Advance clinical milestones for CS1 and CS014** (short-term) — Clinical data and trial progress are the main value drivers for a biotech without commercial revenue. - **Strengthen regulatory positioning** (short-term) — Fast Track and similar designations can improve development efficiency and partnering appeal. - **Build partnering optionality** (medium-term) — Later-stage clinical assets may attract larger pharma partners or licensing discussions. - **Develop the broader HDAC platform** (long-term) — Platform breadth can create multiple shots on goal across cardiopulmonary diseases. - Advance CS1 toward later-stage PAH development - Move CS014 from Phase I into Phase II development - Progress CS585 through preclinical validation - Use FDA and regulatory designations to support development - Pursue partnerships and licensing as programs mature ## Risks The company’s value depends on successful clinical development, regulatory acceptance, and access to financing before any product revenue exists. As a clinical-stage biotech, it also faces binary trial risk, dilution risk, and the possibility that scientific results do not translate into approved therapies or partnering deals. - **Clinical development failure** [critical] — Pipeline value depends on positive safety, efficacy, and tolerability data in small patient populations. - **Financing and dilution risk** [high] — The company is pre-revenue and must fund multi-year trials and regulatory work. - **Regulatory risk** [high] — Trial design, endpoints, and agency feedback can alter timelines and development costs. - **Partnering and commercialization risk** [medium] — Future value may depend on securing collaborations or licensing on favorable terms. - Clinical trial failure could materially reduce pipeline value - Regulatory delays can slow development and partnering - Financing needs may require repeated capital raises - Scientific risk remains high for novel epigenetic mechanisms - Partnering value depends on data quality and timing ## Accounting Cereno Scientific’s reporting is shaped by clinical-stage biotech accounting, where most spending is expensed as research and development and results are highly sensitive to trial timing. Investors should also watch financing instruments such as convertibles and warrants, as well as going-concern judgments and any fair value or dilution effects from equity-linked funding. - **Research and development expense recognition** — Quarterly and annual results can swing with study activity and external service spend - **Convertible loans and warrants** — Reported earnings and share count may be affected by conversion terms - **Going-concern assessment** — Disclosure and valuation depend on financing assumptions - R&D expense timing follows clinical and preclinical activity - Convertible loans and warrants can affect dilution and finance costs - Going-concern assessment depends on future funding access - Share-based incentives may affect operating expenses - No product revenue means results are driven by development spend --- *Last updated: 2026-08-11T04:04:51.551994+00:00*